<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Hims Hers Health Inc — News on 6ix</title>
<link>https://6ix.com/company/hims-hers-health-inc</link>
<description>Latest news and press releases for Hims Hers Health Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:35:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/hims-hers-health-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357e2178dffbe2df0fa779.webp</url>
<title>Hims Hers Health Inc</title>
<link>https://6ix.com/company/hims-hers-health-inc</link>
</image>
<item>
<title>Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-nominates-kofi-amoo-gottfried-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-nominates-kofi-amoo-gottfried-to-its-board-of-directors</guid>
<pubDate>Tue, 28 Apr 2026 12:35:00 GMT</pubDate>
<description>SAN FRANCISCO, April 28, 2026--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the company’s 2026 annual shareholder meeting in June.</description>
</item>
<item>
<title>Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-to-announce-first-quarter-2026-financial-results-on-may-11-2026</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-to-announce-first-quarter-2026-financial-results-on-may-11-2026</guid>
<pubDate>Mon, 13 Apr 2026 20:05:00 GMT</pubDate>
<description>SAN FRANCISCO, April 13, 2026--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results after the market closes on Monday, May 11, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.</description>
</item>
<item>
<title>Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/novo-nordisks-fda-approved-glp-1s-now-available-with-hims-and-hers</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/novo-nordisks-fda-approved-glp-1s-now-available-with-hims-and-hers</guid>
<pubDate>Thu, 26 Mar 2026 16:00:00 GMT</pubDate>
<description>SAN FRANCISCO, March 26, 2026--Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk’s FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and delivery metho</description>
</item>
<item>
<title>Hims & Hers Names Kathryn Beiser as Chief Communications Officer</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-names-kathryn-beiser-as-chief-communications-officer</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-names-kathryn-beiser-as-chief-communications-officer</guid>
<pubDate>Wed, 11 Mar 2026 00:08:00 GMT</pubDate>
<description>SAN FRANCISCO, March 11, 2026--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the indu</description>
</item>
<item>
<title>Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/introducing-hims-and-hers-benefits-unlocking-health-and-wellness-discounts-for-subscribers-3</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/introducing-hims-and-hers-benefits-unlocking-health-and-wellness-discounts-for-subscribers-3</guid>
<pubDate>Tue, 10 Mar 2026 13:00:00 GMT</pubDate>
<description>SAN FRANCISCO, March 10, 2026--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative provides active subscribers access to discounts from health partners, all in one place, including whole body MRI scans from Prenuvo and adaptive bed systems from Eight Sleep. This is just the beginning of a larger benefits program that will make compr</description>
</item>
<item>
<title>Hims & Hers Announces Strategic Shift for US Weight Loss Business</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-announces-strategic-shift-for-us-weight-loss-business</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-announces-strategic-shift-for-us-weight-loss-business</guid>
<pubDate>Mon, 09 Mar 2026 12:30:00 GMT</pubDate>
<description>SAN FRANCISCO, March 09, 2026--Hims & Hers Health, Inc. (NYSE: HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company’s approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international</description>
</item>
<item>
<title>Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-health-inc-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-health-inc-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN FRANCISCO, February 23, 2026--Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com.</description>
</item>
<item>
<title>Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-announces-agreement-to-acquire-eucalyptus-accelerating-its-vision-to-become-the-leading-global-consumer-health-platform</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-and-hers-announces-agreement-to-acquire-eucalyptus-accelerating-its-vision-to-become-the-leading-global-consumer-health-platform</guid>
<pubDate>Thu, 19 Feb 2026 11:00:00 GMT</pubDate>
<description>SAN FRANCISCO, February 19, 2026--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company’s ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japa</description>
</item>
<item>
<title>Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-glp-1-weight-loss-015100273</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-glp-1-weight-loss-015100273</guid>
<pubDate>Fri, 06 Feb 2026 01:51:00 GMT</pubDate>
<description>An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy pill category context, published pricing disclosures, telehealth eligibility considerations, and regulatory factors consumers are researching before choosing a GLP-1 weight loss providerSan Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Weight management concerns should be eva</description>
</item>
<item>
<title>Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-hers-expands-personalized-weight-140000124</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-hers-expands-personalized-weight-140000124</guid>
<pubDate>Thu, 05 Feb 2026 14:00:00 GMT</pubDate>
<description>SAN FRANCISCO, February 05, 2026--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers.</description>
</item>
<item>
<title>Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-hers-launches-multi-cancer-140000143</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-hers-launches-multi-cancer-140000143</guid>
<pubDate>Wed, 04 Feb 2026 14:00:00 GMT</pubDate>
<description>SAN FRANCISCO, February 04, 2026--Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers’ scale with GRAIL’s innovative cancer screening technology to dramatically increase access to proactive care.</description>
</item>
<item>
<title>Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-hers-announce-fourth-quarter-210500405</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-hers-announce-fourth-quarter-210500405</guid>
<pubDate>Mon, 02 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN FRANCISCO, February 02, 2026--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.</description>
</item>
<item>
<title>Hims & Hers Returns to the Big Game with a Message to All Americans: The Era of Health as a Luxury is Over</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-hers-returns-big-game-140000876</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-hers-returns-big-game-140000876</guid>
<pubDate>Thu, 29 Jan 2026 14:00:00 GMT</pubDate>
<description>SAN FRANCISCO, January 29, 2026--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, announced that it’s heading back to the Big Game this year. On February 8th, Hims & Hers will follow up its hit "Sick of the System" ad, debuting a new national spot "Rich People Live Longer" with a simple message: the era of health as a luxury good is over, and proactive, life-changing care belongs to everyone.</description>
</item>
<item>
<title>Cold Spring Harbor Laboratory Appoints Jack Abraham and Terri Keogh to Board of Trustees</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/cold-spring-harbor-laboratory-appoints-jack-abraham-and-terri-keogh-to-board-of-trustees-1</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/cold-spring-harbor-laboratory-appoints-jack-abraham-and-terri-keogh-to-board-of-trustees-1</guid>
<pubDate>Wed, 28 Jan 2026 15:51:00 GMT</pubDate>
<description>The Cold Spring Harbor Laboratory (CSHL) Board of Trustees has elected Jack Abraham to the private not-for-profit institution's governing body. Abraham is the founder, CEO, and managing partner of Atomic, the venture studio behind Hims & Hers, Exowatt, and other successful companies.</description>
</item>
<item>
<title>Hims & Hers Brings Comprehensive Weight Loss Programme to the UK</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-hers-brings-comprehensive-weight-083300228</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-hers-brings-comprehensive-weight-083300228</guid>
<pubDate>Wed, 10 Dec 2025 08:33:00 GMT</pubDate>
<description>Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers. This expansion includes the official introduction of the Hers platform, helping eligible women across the UK receive access to this holistic weight management care.</description>
</item>
<item>
<title>Hims & Hers Continues Major International Expansion With Official Entry Into Canada</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-hers-continues-major-international-120000896</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-hers-continues-major-international-120000896</guid>
<pubDate>Thu, 04 Dec 2025 12:00:00 GMT</pubDate>
<description>SAN FRANCISCO, December 04, 2025--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, is now serving customers in Canada. This entry follows the recent completion of Hims & Hers’ acquisition of Livewell, a trusted Canadian digital health platform offering access to a variety of treatments, with a focus on weight loss. Building on a strong foundation in both the US and Europe, the entry into Canada positions Hims & Hers to lead the next era of dig</description>
</item>
<item>
<title>Hims & Hers Now Serving Customers in Canada</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-hers-now-serving-customers-120000445</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-hers-now-serving-customers-120000445</guid>
<pubDate>Thu, 04 Dec 2025 12:00:00 GMT</pubDate>
<description>MONTREAL, December 04, 2025--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, is now serving customers in Canada. This entry follows the recent acquisition of Livewell, a trusted Canadian digital health platform focused on weight loss. Through this expansion, Hims & Hers is well-positioned to usher in the next era of digital health to Canada, bringing its established commitment to providing access to affordable, personalized, and customer-firs</description>
</item>
<item>
<title>Hims & Hers to Acquire YourBio Health, Pioneer Behind Advanced, Pain-Free Blood Sampling Technology</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-hers-acquire-yourbio-health-140000973</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-hers-acquire-yourbio-health-140000973</guid>
<pubDate>Wed, 03 Dec 2025 14:00:00 GMT</pubDate>
<description>SAN FRANCISCO & BOSTON, December 03, 2025--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced that it has entered into a definitive agreement to acquire YourBio Health, Inc., a Boston-based pioneer in capillary whole blood sampling technology. Powered by YourBio’s advanced blood sampling devices, the acquisition will help accelerate efforts to redefine and modernize the overall blood collection experience, making pain-free blood sampling the new stan</description>
</item>
<item>
<title>Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-hers-health-inc-announces-130000885</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-hers-health-inc-announces-130000885</guid>
<pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
<description>SAN FRANCISCO, November 17, 2025--Hims & Hers Health, Inc. ("Hims & Hers" or the "Company," NYSE: HIMS), the leading health and wellness platform, today announced that its Board of Directors has authorized a share repurchase program of up to $250 million of outstanding Class A common stock over the next three years. This new program follows the successful completion of the Company’s prior $100 million share repurchase program, established in July 2024, which has now been fully utilized.</description>
</item>
<item>
<title>Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy</title>
<link>https://6ix.com/company/hims-hers-health-inc/news/hims-hers-names-deb-autor-110000388</link>
<guid isPermaLink="true">https://6ix.com/company/hims-hers-health-inc/news/hims-hers-names-deb-autor-110000388</guid>
<pubDate>Mon, 17 Nov 2025 11:00:00 GMT</pubDate>
<description>SAN FRANCISCO, November 17, 2025--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company’s first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the fut</description>
</item>
</channel>
</rss>